Liver function and drug processing: a new study on capivasertib
NCT ID NCT07343960
First seen Jan 15, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study looks at how a single dose of capivasertib is processed by the body in people with moderate liver impairment compared to those with normal liver function. About 20 participants will take part. The goal is to understand safety and drug levels, not to treat a disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGRialto, California, 92377, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.